Rheumatoid Arthritis Stocks
Biopharmaceutical developers and diagnostic providers in this cohort focus on systemic autoimmune conditions characterized by chronic synovial inflammation and progressive joint destruction.
As of Oct 23, 2026, Rheumatoid Arthritis has 12 US-listed companies worth $2.9T combined. The median member moved +2.0% over the past week; MLTX led at +24.1% and APUS trailed at -28.5%.
Companies in Rheumatoid Arthritis
- LLY – Eli Lilly and Company, $1.1T
- JNJ – Johnson & Johnson, $645B
- ABBV – AbbVie Inc, $505B
- AMGN – Amgen Inc, $237B
- PFE – Pfizer Inc, $171B
- BMY – Bristol-Myers Squibb Company, $129B
- SNY – Sanofi ADR, $99.7B
- IMVT – Immunovant Inc, $5.9B
- JBIO – Jade Biosciences, Inc., $853M
- MLTX – MoonLake Immunotherapeutics, $813M
- XGN – Exagen Inc, $198M
- APUS – Apimeds Pharmaceuticals US, Inc., $6.1M